CONMED Corp.
- CNMD · NYSE
- Electromedical & Electrotherapeutic Apparatus
- Largo, FL
- 3,900 employees
- CIK 0000816956
Updated from SEC filings through
Top things to know
Executives
- Patrick J. Beyer CONMED’s President and Chief Executive Officer 8-K, 2026-10-28
- Patrick Beyer President and Chief Executive Officer 8-K, 2026-06-17
- Pat Beyer President & CEO 4, 2026-04-02
- John E. Gallagher Executive Vice President & CFO 4, 2026-07-17
- Todd W. Garner Executive Vice President & CFO 4, 2025-11-07
- John D. Ferrell Executive Vice President - HR 4/A, 2026-03-18
What leadership is saying
“Our third quarter organic, constant currency net sales growth was consistent with our expectations and our adjusted diluted EPS exceeded them, reflecting our team’s strong execution”
Earnings press release (8-K Ex. 99.1), filed October 28, 2026
CONMED Corp is a U.S. public company in electromedical & electrotherapeutic apparatus (SIC 3845), headquartered in Largo, FL. It trades as CNMD on NYSE. Revenue was $1.4B in the fiscal year ending December 31, 2025, +5.2% from the year before. It reported about 3,900 employees. Patrick J. Beyer is CONMED’s President and Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.4B 10-K, 2026-02-17 | $1.3B 10-K, 2026-02-17 | $1.2B 10-K, 2026-02-17 | $1.0B 10-K, 2025-02-18 | $1.0B 10-K, 2024-02-28 |
| Operating income | $103M 10-K, 2026-02-17 | $200M 10-K, 2026-02-17 | $121M 10-K, 2026-02-17 | $70.1M 10-K, 2025-02-18 | $110M 10-K, 2024-02-28 |
| SG&A | $592M 10-K, 2026-02-17 | $478M 10-K, 2026-02-17 | $503M 10-K, 2026-02-17 | $454M 10-K, 2025-02-18 | $415M 10-K, 2024-02-28 |
| Net income | $47.1M 10-K, 2026-02-17 | $132M 10-K, 2026-02-17 | $64.5M 10-K, 2026-02-17 | -$80.6M 10-K, 2025-02-18 | $62.5M 10-K, 2024-02-28 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Patrick J. Beyer President, Chief Executive Officer at CONMED Corporation | CONMED’s President and Chief Executive Officer | 8-K, 2026-10-28 |
| Patrick Beyer | President and Chief Executive Officer | 8-K, 2026-06-17 |
| Pat Beyer President, Chief Executive Officer at CONMED Corporation | President & CEO | 4, 2026-04-02 |
| John E. Gallagher Chief Financial Officer at Certara | Executive Vice President & CFO | 4, 2026-07-17 |
| Todd W. Garner | Executive Vice President & CFO | 4, 2025-11-07 |
| John D. Ferrell | Executive Vice President - HR | 4/A, 2026-03-18 |
| Richard Glaze | Chief Information Officer | 4, 2025-11-24 |
| Kimberly Lockwood | Interim Corporate Controller | 8-K, 2026-06-17 |
| Hollie Foust General Counsel and Corporate Secretary, Conmed Corporation | EVP, General Counsel and Corporate Secretary | DEF 14A, 2026-04-07 |
| Johonna Pelletier | Treasurer and VP, Tax | DEF 14A, 2026-04-07 |
| John David Ferrell | EVP, Human Resources | DEF 14A, 2026-04-07 |
| Brent Lalomia Executive Vice President, QA, RA, Clinical & Commercial Operations at CONMED Corporation | Executive VP RA, QA | 4/A, 2026-03-18 |
| Hollie K. Foust | General Counsel & Corp Sec | 4/A, 2026-03-18 |
| Peter K. Shagory | EVP, STRAT & CORP DEVT | 4/A, 2026-03-18 |
| Matthew Schabacker | VP GM Advanced Surgical | 4/A, 2026-03-18 |
| Andrew James Moller | VP Corporate Controller | 4, 2026-03-04 |
What CONMED Corp does
general economic and business conditions, including, without limitation, a potential economic downturn, supply chain challenges and constraints, including the availability and cost of materials, the effects of inflation, and increased interest rates;
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 29.8 million (as of October 26, 2026) | 10-Q, October 28, 2026 |
|---|---|---|
| Public float | $1.2B (as of June 30, 2025) | 10-K, February 17, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, October 28, 2026 |
| Latest proxy statement | Meeting May 18, 2026 (filed April 7, 2026) | DEF 14A, April 7, 2026 |
| Auditor | PricewaterhouseCoopers LLP (Victor, New York) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 21, 2025 | Richard Glaze Chief Information Officer | Sale | 257 | $11K | Form 4, November 24, 2025 |
| November 6, 2025 | Todd W. Garner Executive Vice President & CFO | Sale | 3,500 | $151K | Form 4, November 7, 2025 |
| September 12, 2025 | Charles Farkas Director | Sale | 2,000 | $107K | Form 4, September 15, 2025 |
| August 7, 2025 | Todd W. Garner Executive Vice President & CFO | Sale | 598 | $31K | Form 4, August 8, 2025 |
Recent 8-K events
- 8-K filed 2026-10-28
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-29
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-17
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-04
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-06-01
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- 8-K filed 2026-05-20
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-04-29
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-13
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-01-28
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-01-12
- Item 7.01 Regulation FD disclosure
Frequently asked questions about CONMED Corp
- What does CONMED Corp do?
- In its own words, from Item 1 of its 10-K: "general economic and business conditions, including, without limitation, a potential economic downturn, supply chain challenges and constraints, including the availability and cost of materials, the effects of inflation, and increased interest rates;"
- What is CONMED Corp's revenue?
- $1.4B for the fiscal year ending December 31, 2025, from its 10-K filed February 17, 2026.
- Is CONMED Corp profitable?
- CONMED Corp reported net income of $47.1M for the fiscal year ending December 31, 2025.
- How many employees does CONMED Corp have?
- About 3,900 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of CONMED Corp?
- Patrick J. Beyer, CONMED’s President and Chief Executive Officer, as named in a 8-K filed October 28, 2026.
- Who is the CFO of CONMED Corp?
- John E. Gallagher, Executive Vice President & CFO, as named in a 4 filed July 17, 2026.
- Where is CONMED Corp headquartered?
- Largo, FL.
- What is CONMED Corp's stock ticker?
- CNMD on NYSE.
- What industry is CONMED Corp in?
- Electromedical & Electrotherapeutic Apparatus, SIC code 3845.
- What is CONMED Corp's website?
- conmed.com.
- When does CONMED Corp report earnings next?
- January 27, 2027. Source: estimate_8k_pattern.
- Is CONMED Corp a public company?
- Yes. CONMED Corp files with the SEC under CIK 0000816956 and trades as CNMD.
- Who audits CONMED Corp?
- PricewaterhouseCoopers LLP, Victor, New York, as named in its latest annual report (10-K).
- How many shares of CONMED Corp are outstanding?
- 29.8 million shares as of October 26, 2026, from its 10-Q filed October 28, 2026.
- What is CONMED Corp's public float?
- $1.2B as of June 30, 2025, as reported on the cover of its 10-K filed February 17, 2026.
- How many business segments does CONMED Corp report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed October 28, 2026.
- When is CONMED Corp's annual shareholder meeting?
- May 18, 2026, per its proxy statement (DEF 14A) filed April 7, 2026.
- Have CONMED Corp insiders traded stock recently?
- Since August 7, 2025, officers and directors reported 4 open-market sales worth about $300K and 0 purchases on Forms 4 and 5. The most recent: Richard Glaze (Chief Information Officer) sold 257 shares on November 21, 2025.